Botensilimab is a monoclonal antibody commercialized by Agenus, with a leading Phase II program in Metastatic Colorectal Cancer. According to Globaldata, it is involved in 11 clinical trials, of which 8 are ongoing, and 3 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Botensilimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Botensilimab is expected to reach an annual total of $63 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
AGEN-1181 is under development for the treatment of solid tumors including angiosarcoma and microsatellite stable tumors but not limited to PD-1-refractory non-small-cell lung cancer, ovarian cancer and MSS-colorectal cancer, renal cell carcinoma, metastatic castration-resistant prostate cancer (mCRPC), endometrial cancer, cervical cancer, hepatocellular carcinoma, pancreatic ductal adenocarcinoma, metastatic pancreatic cancer, leiomyosarcoma and colorectal cancer. The therapeutic candidate is administered through intravenous route. It is developed based on retrocyte display technology. The therapeutic candidate acts by targeting cytotoxic T lymphocyte-associated molecule-4 (CTLA-4).
It was also under development for the treatment of melanoma.
Agenus, formerly, Antigenics, is a clinical-stage immuno-oncology company that discovers, develops and commercializes immunotherapeutics for the treatment of various types of cancers and infectious diseases. The company’s pipeline portfolio encompasses vaccines for glioblastoma, genital herpes, and multiple cancer types; vaccine adjuvants for the treatment of shingles and malaria; and checkpoint antibodies targeted at various diseases. The company’s technology portfolio includes antibody discovery platform, vaccine platforms and Heat Shock Protein (HSP) platform. It operates in the US and Europe. Agenus is headquartered in Lexington, Massachusetts, the US.
The company reported revenues of (US Dollars) US$98 million for the fiscal year ended December 2022 (FY2022), a decrease of 66.8% over FY2021. The operating loss of the company was US$181.4 million in FY2022, compared to an operating profit of US$31.9 million in FY2021. The net loss of the company was US$220.1 million in FY2022, compared to a net loss of US$23.9 million in FY2021. The company reported revenues of US$24.3 million for the third quarter ended September 2023, a decrease of 3.9% over the previous quarter.
For a complete picture of Botensilimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.